TrialPloS one2016

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

David A Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.